Fitzpatrick Veronica1, Rivelli Anne2, Blair Christopher2, Copeland Kenneth3, Richards Jon4. 1. Advocate Aurora Health, Downers Grove, IL, 60515; Advocate Aurora Research Institute, Downers Grove, IL, 60515. Electronic address: Veronica.fitzpatrick@aah.org. 2. Advocate Aurora Health, Downers Grove, IL, 60515; Advocate Aurora Research Institute, Downers Grove, IL, 60515. 3. Advocate Aurora Health, Downers Grove, IL, 60515; ACL Laboratories - Wisconsin and Illinois, Rosemont, IL 60018; West Allis, WI 53227. 4. Advocate Aurora Health, Downers Grove, IL, 60515.
Abstract
PURPOSE: To quantify COVID-19 recurrence among clinical and non-clinical healthcare employees with SARS-CoV-2 IgG antibodies or prior COVID-19 infection. METHODS: This prospective, cohort study collected and resulted SARS-CoV-2 IgG serum samples as positive or negative from June 8 to July 10, 2020 from a convenience sample of 16,233 adult participants employed by a large Midwestern healthcare system. Documented positive PCR test results representing COVID-19 infections were recorded up to four months prior to and post-IgG testing. RESULTS: 913 (6.12%) participants, including 45 (4.93%) IgG positive participants, experienced COVID-19 infections after study initiation, representing a 51% increased risk of COVID-19 infection among IgG positive participants (IRR=1.51). Regressions adjusted for documented disparities showed no difference in COVID-19 infection by IgG status (OR=1.19; p=0.3117) but significantly greater odds in COVID-19 recurrence among participants with a prior documented COVID-19 infection (OR=1.93; p<0.0001). CONCLUSIONS: SARS-CoV-2 IgG antibodies and prior COVID-19 infection do not appear to offer meaningful protection against COVID-19 recurrence in healthcare workers. Recurrence would impact decisions regarding ongoing healthcare resource utilization. This study can inform considerations for vaccine administration to vulnerable groups.
PURPOSE: To quantify COVID-19 recurrence among clinical and non-clinical healthcare employees with SARS-CoV-2 IgG antibodies or prior COVID-19infection. METHODS: This prospective, cohort study collected and resulted SARS-CoV-2 IgG serum samples as positive or negative from June 8 to July 10, 2020 from a convenience sample of 16,233 adult participants employed by a large Midwestern healthcare system. Documented positive PCR test results representing COVID-19infections were recorded up to four months prior to and post-IgG testing. RESULTS: 913 (6.12%) participants, including 45 (4.93%) IgG positive participants, experienced COVID-19infections after study initiation, representing a 51% increased risk of COVID-19infection among IgG positive participants (IRR=1.51). Regressions adjusted for documented disparities showed no difference in COVID-19infection by IgG status (OR=1.19; p=0.3117) but significantly greater odds in COVID-19 recurrence among participants with a prior documented COVID-19infection (OR=1.93; p<0.0001). CONCLUSIONS:SARS-CoV-2 IgG antibodies and prior COVID-19infection do not appear to offer meaningful protection against COVID-19 recurrence in healthcare workers. Recurrence would impact decisions regarding ongoing healthcare resource utilization. This study can inform considerations for vaccine administration to vulnerable groups.
Authors: Eli D Ehrenpreis; Sigrun Hallmeyer; David H Kruchko; Alexea A Resner; Nhan Dang; Natasha Shah; Nancy Mayer; Anne Rivelli Journal: Healthcare (Basel) Date: 2022-02-01
Authors: Ana Atti; Ferdinando Insalata; Edward J Carr; Ashley D Otter; Javier Castillo-Olivares; Mary Wu; Ruth Harvey; Michael Howell; Andrew Chan; Jonathan Lyall; Nigel Temperton; Diego Cantoni; Kelly da Costa; Angalee Nadesalingam; Andrew Taylor-Kerr; Nipunadi Hettiarachchi; Caio Tranquillini; Jacqueline Hewson; Michelle J Cole; Sarah Foulkes; Katie Munro; Edward J M Monk; Iain D Milligan; Ezra Linley; Meera A Chand; Colin S Brown; Jasmin Islam; Amanda Semper; Andre Charlett; Jonathan L Heeney; Rupert Beale; Maria Zambon; Susan Hopkins; Tim Brooks; Victoria Hall Journal: J Infect Date: 2022-09-09 Impact factor: 38.637